Cannabis Abstinence and Neurocognitive Assessment in Adolescence

NCT07160153 | Recruiting

• 1 other identifier: CANAA
• Study Type: observational
• Target: 29
• Locations: 1 country
• Sites: 1

Brief Summary

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Conditions

Cannabis Dependence; Harmful Use; Cognitive Assessment

Keywords

Cannabis Dependence; Cannabis Use Disorder; Abstinence; Cognitive Function; Disorder; Abstinence; Cognitive Function; Neuropsychological

Outcome Measures

Primary Outcomes (1)

• Change in performance TMT-B

  Change in performance on the Trail Making Test - Part B (TMT-B) \[Time Frame: after 8 weeks of abstinence from cannabis\]

  8 weeks

Secondary Outcomes (4)

• Change in performance on AVLT

  8 weeks

• Change in performance on the Stroop Test

  8 weeks

• Change in performance on the Tower of London

  8 weeks

• Change in performance on CPT-IP

  8 weeks

Other Outcomes (1)

• Cannabis Abuse Screening Test versus degree of neurocognitive impairment

  8 weeks

Study Arms (1)

Group 1

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Diagnostic Test: Neurocognitive assessment; Diagnostic Test: Urine toxicological assessment

Interventions

Neurocognitive assessment DIAGNOSTIC_TEST

Neurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs Other psychometrics: The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)

Group 1

Urine toxicological assessment DIAGNOSTIC_TEST

Urine toxicological assessment

Group 1

Eligibility Criteria

• Age: 15 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

You may qualify if:

• Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

You may not qualify if:

• psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
• somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
• Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.

Sponsors & Collaborators

• University Hospital Pilsen: lead

Study Sites (1)

University Hospital Pilsen

Pilsen, Czechia, 30100, Czechia

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Urine

MeSH Terms

Conditions

Marijuana Abuse

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Central Study Contacts

Jiri Podlipny, MD, Ph.D.

CONTACT

+420 377 103 209; podlipny@fnplzen.cz

Frantisek Nekvapil, MD

CONTACT

+420 377 103 101; nekvapilfr@fnplzen.cz

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2025
• First Posted: September 8, 2025
• Study Start: December 3, 2024
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): August 31, 2029
• Last Updated: September 19, 2025

Record last verified: 2025-08

Locations

CZ (1)